Cellectar Biosciences, Inc. (CLRB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on January 30, 2025. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "CLRB". The filing addresses a specific regulatory notice regarding continued listing standards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance matter and does not contain financial performance data.
Material Changes
On January 30, 2025, the Company received notice from Nasdaq indicating non-compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 for continued listing. The stock remains listed on the Nasdaq Capital Market with no immediate impact on trading status.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has 180 calendar days, until July 29, 2025, to regain compliance with the $1.00 minimum bid price requirement.
- Extension Criteria: If compliance is not met within the initial 180 days, the Company may be eligible for an additional 180-day period. Qualification requires meeting the market value of publicly held shares and all other initial listing standards (except the bid price) and providing written notice of intent to cure, potentially via a reverse stock split.
- Delisting Risk: There is no assurance the Company will attain compliance. Failure to regain compliance within any granted period could result in a delisting determination.
- Remedies: In the event of a delisting determination, the Company may request a hearing before a Nasdaq Hearings Panel, which would stay any delisting action.
Key Facts for Investor Verification
- Verify the current trading price of CLRB relative to the $1.00 minimum bid price requirement.
- Monitor the Company's market value of publicly held shares to assess eligibility for a potential second compliance period.
- Watch for announcements regarding a potential reverse stock split as a method to cure the deficiency.
- Track the July 29, 2025 deadline for the initial compliance period.